Contineum Therapeutics, Inc. (CTNM)

Contineum Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-56.86	-42.26	22.72	-24.25	-29
Depreciation & Amortization	0.29	0.26	0.2	0.33	0.33
Other Amortization	-	-	-	-	0.15
Loss (Gain) From Sale of Assets	0.05	-0.02	-	0	-
Loss (Gain) From Sale of Investments	-2.55	-3.95	-2.66	0.25	0.39
Stock-Based Compensation	9.53	6.8	2.22	1.93	1.75
Other Operating Activities	0.84	0.98	-2.11	2.9	0.01
Change in Accounts Payable	1.23	1.14	-	-0.23	-0.11
Change in Other Net Operating Assets	1.02	4.19	-1.02	-1.04	0.22
Operating Cash Flow	-46.44	-32.85	19.35	-20.12	-26.27
Capital Expenditures	-0.34	-0.51	-0.41	-0.12	-0.17
Sale of Property, Plant & Equipment	0.02	0.02	-	-	-
Investment in Securities	-10.45	-69.25	-65.15	22.42	-64.8
Investing Cash Flow	-10.77	-69.74	-65.57	22.3	-64.97
Long-Term Debt Repaid	-	-	-3.75	-1.25	-
Net Debt Issued (Repaid)	-	-	-3.75	-1.25	-
Issuance of Common Stock	0.95	109	0.16	0.02	0.11
Repurchase of Common Stock	-	-	-0.03	-0	-
Other Financing Activities	-0.18	-	-0.34	-	-
Financing Cash Flow	0.77	109	56.18	-1.24	79.84
Net Cash Flow	-56.45	6.42	9.96	0.94	-11.4
Free Cash Flow	-46.78	-33.36	18.94	-20.24	-26.43
Free Cash Flow Margin	-	-	37.87%	-	-
Free Cash Flow Per Share	-1.81	-1.72	5.58	-9.02	-12.53
Cash Interest Paid	-	-	0.15	0.23	0.22
Cash Income Tax Paid	-	-	0.45	-	-
Levered Free Cash Flow	-31.71	-20.87	13.08	-12.61	-
Unlevered Free Cash Flow	-31.71	-20.87	13.21	-12.37	-
Change in Net Working Capital	-2.81	-4.39	-1.17	0.31	-

Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q